美国2型糖尿病患者中非酒精性脂肪性肝炎的经济与临床负担
该研究构建Markov模型,评估美国2型糖尿病合并NASH患者20年经济与临床负担。
要点
- 干预措施可能降低NASH合并T2DM患者的临床与经济负担。
核心结论
- 模型预测未来20年NASH合并T2DM将带来显著的临床和经济负担。
- 由于采用保守输入且未增加费用或T2DM发病率,实际负担可能更大。
- 减少NASH合并T2DM患者发病率与死亡率的干预可能降低预测负担。
研究设计与样本
- 构建Markov模型,1年周期,20年时间跨度,估计美国NASH合并T2DM的经济负担。
- 队列规模基于2017年人口数、T2DM患病率及NASH患病率和发病率确定。
- 模型包括10个健康状态及肝脏相关、心血管和背景死亡率,转移概率来自荟萃分析和文献。
临床怎么用
- 内分泌科医生应关注T2DM患者中NASH的筛查与管理以减轻长期负担。
局限性
- 模型采用保守输入,未随时间增加费用或T2DM发病率,可能低估实际负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease (NAFLD) and is strongly associated with type 2 diabetes mellitus (T2DM). Patients with both T2DM and NASH have increased risk for adverse clinical outcomes, leading to higher risk for mortality and morbidity. We built a Markov model with 1-year cycles and 20-year horizon to estimate the economic burden of NASH with T2DM in the U.S. RESEARCH DESIGN AND METHODS: Cohort size was determined by population size, prevalence of T2DM, and prevalence and incidence of NASH in 2017. The model includes 10 health states-NAFL, NASH fibrosis stages F0 through F3, compensated and decompensated cirrhosis, hepatocellular carcinoma, 1 year post-liver transplant, and post-liver transplant-as well as liver-related, cardiovascular, and background mortality. Transition probabilities were calculated from meta-analyses and literature. Annual costs for NASH and T2DM were taken from literature and billing codes. RESULTS: We estimated that there were 18.2 million people in the U.S. living with T2DM and NAFLD, of which 6.4 million had NASH. Twenty-year costs for NAFLD in these patients were $55.8 billion. Over the next 20 years, NASH with T2DM will account for 65,000 transplants, 1.37 million cardiovascular-related deaths, and 812,000 liver-related deaths. CONCLUSIONS: This model predicts significant clinical and economic burden due to NASH with T2DM over the next 20 years. In fact, this burden may be greater since we assumed conservative inputs for our model and did not increase costs or the incidence of T2DM over time. It is highly likely that interventions reducing morbidity and mortality in NASH patients with T2DM could potentially reduce this projected clinical and economic burden.
引用
- Younossi ZM, Tampi RP, Racila A, et al. Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S. Diabetes Care. 2019. PMID: 31658974. doi:10.2337/dc19-1113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。